Results from two Phase 3 clinical trials of a novel oral Janus kinase (JAK) inhibitor for vitiligo have shown significant repigmentation in patients with non-segmental vitiligo affecting the face and body.

Trial Results

After 52 weeks of treatment, approximately 50% of patients achieved at least 75% improvement in facial vitiligo (F-VASI75), compared to just 5% in the placebo group. Body repigmentation also showed meaningful improvement.

Safety Profile

The oral JAK inhibitor was generally well-tolerated with a safety profile consistent with the class. Common side effects included acne, headache, and upper respiratory tract infections.

Impact on Patient Care

This represents a major advance for vitiligo patients who have historically had limited treatment options. If approved, this would be among the first oral systemic therapies specifically indicated for vitiligo.